Press Release

Printer Friendly Version View printer-friendly version
<< Back
POZEN Names Dr. Everardus Orlemans as Vice President, Clinical Research

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Nov. 16, 2005--POZEN Inc. (NASDAQ: POZN), a pharmaceutical company focused primarily on products for the treatment of acute and chronic pain, migraine, and other pain-related conditions, today announced the appointment of Everardus Orlemans, Ph.D. as Vice President, Clinical Research. Dr. Orlemans will be responsible for all of the company's efforts in the conduct of clinical trials to support New Drug Application (NDA) submissions to the Food and Drug Administration (FDA) and other worldwide regulatory bodies.

Dr. Marshall Reese, POZEN's Executive Vice President, Product Development, said, "We are very pleased to have Dr. Orlemans as a part of the POZEN team. Dr. Orlemans has made contributions of major significance in the field of clinical development in Europe, Japan as well as the United States. In particular, his extensive international experience with regulatory submissions will be a great asset to POZEN."

Dr. Orlemans has been responsible for the worldwide submissions/approvals of more than ten NDAs in the United States and another three NDAs in other major markets around the globe. Dr. Orlemans is the co-author of five patents. He began his professional career in clinical development with Organon NV, a renowned pharmaceutical company in The Netherlands before transferring to the United States for Organon Pharmaceuticals USA, Inc. Most recently, Dr. Orlemans was Executive Director of the Clinical Development Unit for Organon in the United States.

Dr. Orlemans received a Master of Science degree in Chemistry from Catholic University of Nijmegen located in The Netherlands. He received a Ph.D. degree from the University of Twente, also located in The Netherlands.


POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. Since its inception, POZEN has focused its efforts primarily on the development of pharmaceutical products for the treatment of migraine. POZEN is also exploring the development of product candidates in other acute and chronic pain and pain-related therapeutic areas. POZEN has a development and commercialization alliance with GlaxoSmithKline. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website:

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies, or the failure to obtain such approval of our product candidates, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in or unexpected clinical trial results or uncertainties in the timing of clinical trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2005 under "Management's Discussion and Analysis of Financial Condition and Results of Operations." We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

Bill Hodges, Chief Financial Officer
919-913-1030 or
Fran Barsky, Director, Investor Relations


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.